Latest News

Methylone (TSND-201) for PTSD Shows Rapid, Sustained Symptom Improvement in Phase 2 IMPACT-1 Trial April 1, 2025 / image credit ©Feng Yu/stock.adobe.com
Methylone (TSND-201) for PTSD Shows Rapid, Sustained Symptom Improvement in Phase 2 IMPACT-1 Trial

April 1st 2025

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

Pediatric Fentanyl Poisonings Spiral Up 1,200% Over 8 Years, Study Finds
Pediatric Fentanyl Poisonings Spiral Up 1,200% Over 8 Years, Study Finds

March 28th 2025

Nearly Half of Adults Diagnosed with MDD May Have Treatment Resistant Depression  / image credit Steven Marwahah, PhD, University of Birmingham
Nearly Half of Adults Diagnosed with MDD May Have Treatment Resistant Depression, Many Feel Hopeless

March 25th 2025

FDA Pre-NDA Meeting for AXS-05 in Alzheimer's Disease Sets Stage for sNDA Submission in Q3 2025 / image credit ©David/stock.adobe.com
FDA Pre-NDA Meeting for AXS-05 in Alzheimer's Disease Sets Stage for sNDA Submission in Q3 2025

March 4th 2025

Latest CME Events & Activities

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Southern Florida Psychiatry Conference

November 21-22, 2025

Register Now!

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

Optimizing Care for Patients With Tardive Dyskinesia

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

More News

© 2025 MJH Life Sciences

All rights reserved.